Inflammation surges earliest in CKM syndrome — before any obvious disease. A new study finds that hsCRP nearly doubles just from having excess body fat (stage 1 CKM), well before hypertension, diabetes, or kidney disease develops. Researchers say this makes early adiposity the prime window for intervention — and a simple waist measurement could be the first clue.
New research reveals that systemic inflammation doesn't gradually build across cardiovascular-kidney-metabolic (CKM) syndrome — it spikes hardest and earliest, driven by excess body fat. A study published in the European Journal of Preventive Cardiology, analyzing data from over 4,300 U.S. adults, found that high-sensitivity C-reactive protein (hsCRP) — a key inflammation marker — nearly doubled between stage 0 (no risk factors) and stage 1 (adiposity alone), long before any metabolic or cardiovascular disease appears.
After that early surge, inflammation rises only modestly through stages 2 and 3, then plateaus at stage 4 — likely because patients at that point are already on statins and other anti-inflammatory therapies. A separate study of nearly 87,000 participants confirmed that elevated hsCRP had its strongest impact on mortality risk at stage 1, with its predictive power fading by advanced disease.
By the Numbers
Why it matters: These findings suggest that stage 1 CKM — defined simply by excess body fat — is the optimal window for inflammation screening and early intervention. Clinicians may not need complex lab panels; even a waist circumference measurement could flag patients who need more intensive preventive care before overt disease sets in.
